Login to Your Account

Roche Licenses DNA Immunotherapies in Prostate Cancer, Hep-B

By Peter Winter
BioWorld Insight Editor

Tuesday, September 10, 2013
Basel, Switzerland-based Roche AG is partnering with Inovio Pharmaceuticals Inc. and will develop DNA-based vaccines INO-5150, targeting prostate cancer, and INO-1800, targeting hepatitis B. The exclusive worldwide license agreement sees Roche make an up-front payment of $10 million and will provide preclinical R&D support and near-term regulatory milestones.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription